Caris Life Sciences announced today that the The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has joined Caris’ Precision Oncology Alliance™ (POA).
The Ohio State University Comprehensive Cancer Center strives to eradicate cancer from individuals’ lives by integrating groundbreaking research with excellence in education and patient-centered care |
| [08-February-2022] |
| IRVING, Texas, Feb. 8, 2022 /PRNewswire/ -- Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that the The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.
OSUCCC – James is one of 51 National Cancer Institute (NCI)-designated comprehensive cancer centers and one of only a few centers funded by the NCI to conduct phase I, II and III clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program’s 356-bed adult patient-care component, OSUCCC - James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice. “We know that there is no routine cancer and that no two patients or cancers are exactly alike, and believe that studying large numbers of patients and their tissues will help us move cancer research toward true personalized and effective cancer care,” said Raphael Pollock, M.D., Ph.D., Director, The Ohio State University Comprehensive Cancer Center. “We are excited to join Caris’ POA, as its mission aligns with our comprehensive approach to cancer care, designed to help us understand the differences between cancer patients and to find ways to individualize prevention, detection and treatment of patients with cancer.” The OSUCCC - James strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care — a strategy that leads to better methods of prevention, detection and treatment. With 21 floors and more than 1.1 million square feet, the transformational facility fosters collaboration and integration of cancer research and clinical cancer care. “We are thrilled to welcome the OSUCCC – James into our growing POA network,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “Together, we will work on optimizing big data, artificial intelligence, machine learning, and innovative ideas to further high-quality research that leads to advances in cancer prevention, detection, diagnosis and treatment.” The Caris Precision Oncology Alliance includes 59 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1,000,000 data points per patient. “The OSUCCC – James is a recognized leader in innovative and personalized cancer care,” said Brian J. Brille, Vice Chairman of Caris Life Sciences. “Their matrixed, university-based approach serves as a model for other POA members and has allowed OSUCCC-James to provide leading-edge care while developing comprehensive treatment plans specifically designed for each patient they serve.” About Caris Life Sciences With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris’ latest advancement, which is currently available within its Precision Oncology Alliance, is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS). About The Ohio State University Comprehensive Cancer Center Caris Life Sciences Media Contact: The Ohio State University Comprehensive Cancer Center Media Contact:
SOURCE Caris Life Sciences |
View original content to download multimedia:
